Stock

Moderna CEO Bancel steps down as sales chief, Bloomberg News reports

(Reuters) -Vaccine maker Moderna (NASDAQ:MRNA)’s chief executive officer Stephane Bancel will vacate his role as the company’s chief commercial officer, Bloomberg News reported on Tuesday citing one person familiar with the matter.

The company’s president Stephen Hoge will take charge of sales as well as medical and research affairs, according to the report.

Bancel will remain in his role as Moderna’s CEO, the report added. Moderna did not immediately respond to a Reuters request for comment.

Moderna had announced in December Bancel would head sales and marketing, and work directly with the company’s commercial team, after then commercial officer Arpa Garay had decided to leave.

This post appeared first on investing.com

You May Also Like

Editor's Pick

Sen. JD Vance (R-Ohio) and Minnesota Gov. Tim Walz (D) will face off Tuesday night at a CBS News vice-presidential debate in New York....

Latest News

A North Korean defector who escaped to the South more than a decade ago was detained after attempting to cross back into North Korea...

Economy

A U.N. human rights group confirmed Hamas’ leader in Lebanon, who was recently killed by Israeli strikes, was their employee.  Fateh Sherif was killed...

Investing

Astron (ASX:ATR) and Energy Fuels (TSX:EFR,NYSEAMERICAN:UUUU) have completed the establishment of a joint venture to advance the Australia-based Donald rare earths and mineral sands...

Disclaimer: balanceandcharge.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 balanceandcharge.com

Exit mobile version